Literature DB >> 11882632

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.

John D Imig1, Xueying Zhao, Jorge H Capdevila, Christophe Morisseau, Bruce D Hammock.   

Abstract

Epoxyeicosatrienoic acids (EETs) have antihypertensive properties and play a part in the maintenance of renal microvascular function. A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conversion of biologically active EETs to dihydroxyeicosatrienoic acids (DHETs) that are void of effects on the preglomerular vasculature. We hypothesized that inhibition of soluble epoxide hydrolase (sEH) would lower blood pressure in angiotensin II (Ang II) hypertension. Rat renal cortical tissue was harvested and urine collected 2 weeks following implantation of an osmotic minipump containing Ang II (60 ng/min). Renal cortical sEH protein expression was significantly higher in Ang II hypertension compared with normotensive animals. Likewise, urinary 14,15-DHET levels were significantly increased in hypertensive compared with normotensive animals and averaged 8.1 +/- 1.3 and 2.7 +/- 1.1 ng/d; respectively. In additional experiments, the sEH inhibitor N-cyclohexyl-N-dodecyl urea (NCND; 3 mg/d) or vehicle (corn oil, 0.5 mL) was administered daily by intraperitoneal injection starting on day 10. Administration of NCND for 4 days lowered systolic blood pressure by 30 mm Hg in Ang II hypertensive animals, whereas the corn oil vehicle had no effect on blood pressure in normotensive or Ang II hypertensive animals. Measurement of blood pressure by indwelling arterial catheters in conscious animals with free movement in their cages confirmed that NCND had antihypertensive properties. Arterial blood pressure averaged 119 +/- 5 mm Hg in normotensive, 170 +/- 3 mm Hg in hypertensive and 149 +/- 10 mm Hg in NCND-treated, Ang II-infused animals. Administration of the potential metabolite of NCND, N-cyclohexylformamide to Ang II hypertensive rats did not lower the systolic blood pressure. These studies demonstrate that increased sEH expression in the Ang II hypertensive kidney leads to increased EET hydration. Moreover, sEH plays a role in the regulation of blood pressure, and inhibition of sEH during Ang II hypertension is antihypertensive.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882632     DOI: 10.1161/hy0202.103788

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  168 in total

1.  N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase.

Authors:  Hsin-Han Hou; Bruce D Hammock; Kou-Hui Su; Christophe Morisseau; Yu Ru Kou; Susumu Imaoka; Ami Oguro; Song-Kun Shyue; Jin-Feng Zhao; Tzong-Shyuan Lee
Journal:  Cardiovasc Res       Date:  2011-11-08       Impact factor: 10.787

Review 2.  Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease.

Authors:  Ning Li; Jun-Yan Liu; Hong Qiu; Todd R Harris; Padmini Sirish; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Congest Heart Fail       Date:  2011-01-27

Review 3.  Key advances in antihypertensive treatment.

Authors:  Ludovit Paulis; Ulrike M Steckelings; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2012-03-20       Impact factor: 32.419

4.  Modulation by salt intake of the vascular response mediated through adenosine A(2A) receptor: role of CYP epoxygenase and soluble epoxide hydrolase.

Authors:  Mohammed A Nayeem; Darryl C Zeldin; Matthew A Boegehold; Christophe Morisseau; Anne Marowsky; Dovenia S Ponnoth; Kevin P Roush; John R Falck
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-04-28       Impact factor: 3.619

5.  Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  Shao-Xu Huang; Hui-Yuan Li; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock; Ya-Qiu Long
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

6.  Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide.

Authors:  Bin Xiao; Xuguang Li; Jiangtao Yan; Xuefeng Yu; Guangtian Yang; Xiao Xiao; James W Voltz; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

7.  A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat.

Authors:  Md Abdul Hye Khan; Sung Hee Hwang; Amit Sharma; John A Corbett; Bruce D Hammock; John D Imig
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-07-16       Impact factor: 3.072

8.  Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Kin Sing Stephen Lee; Diyala S Shihadih; Todd R Harris; Gennady M Butov; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2014-03-20       Impact factor: 2.823

Review 9.  The role of angiotensin II in regulating vascular structural and functional changes in hypertension.

Authors:  Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

10.  Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.

Authors:  In-Hae Kim; In-Hee Lee; Hisashi Nishiwaki; Bruce D Hammock; Kosuke Nishi
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.